SUPPLEMENTARY MATERIAL

Galsky MD, et al. Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.

|  |
| --- |
| **Supplementary Table 1. First-Line Treatments in Patients With Metastatic Bladder Cancer** **With Metastases Limited to Lymph Nodes (any T, N1-3, M0; n = 484)**  |
| **1L Treatmenta** | **n (%)** |
| **Cisplatin-based treatment (n = 77)** |  |
|  Gemcitabine + cisplatin | 61 (12.6) |
|  Cisplatin, single agent | 13 (2.7) |
| **Non–cisplatin-based treatment (n = 144)** |  |
|  Gemcitabine + carboplatin | 58 (12.0) |
|  Other treatments | 29 (6.0) |
|  Gemcitabine, single agent | 15 (3.1) |
|  Carboplatin, single agent | 12 (2.5) |
|  Other single agent | 12 (2.5) |
| **General chemo codesb**  | 18 (3.7) |
| **No evidence of 1L treatment** | 263 (54.3) |

Abbreviation: 1L, first line. a Includes treatment categories with counts > 10. b Patients had evidence of systemic chemotherapy, but the agent was not specified.

|  |
| --- |
| **Supplementary Table 2. Characterization of First- and Second-Line Treatments in Patients With Metastatic Bladder Cancer in the SEER-Medicare Database** |
| **1L treatments** |
|   | **Any 1L Chemotherapy (n = 717)** | **1L Cisplatin Based****(n = 192)** | **1L Non-Cisplatin Based****(n = 525)** | **1L SingleAgent****(n = 156)** | **1L Combination Agent (n = 501)** |
| **Time to 1L treatment, months** |
|  Mean ± SD | 3.8 ± 4.4 | 3.7 ± 4.3 | 3.8 ± 4.5 | 4.0 ± 4.4 | 3.6 ± 4.1 |
|  Median (Q1, Q3) | 2.4 (1.6, 4.1) | 2.5 (1.6, 4.3) | 2.3 (1.6, 4.0) | 2.7 (1.8, 4.1) | 2.3 (1.5, 4.0) |
| **Treatment duration, months** |
|  Median (95% CI) | 2.1 (1.8, 2.3) | 2.8 (2.3, 3.5) | 1.8 (1.6, 2.1) | 1.4 (1.2, 1.6) | 2.7 (2.3, 3.0) |
| **2L treatment, n (%)** |
|  Any | 254 (35.4) | 87 (45.3) | 167 (31.8) | 62 (39.7) | 192 (38.3) |
|  Taxane based | 120 (16.7) | 43 (22.4) | 77 (14.7) | 15 (9.6) | 105 (21.0) |
| **2L treatments** |
|  | **Any 2L Chemotherapy (n = 254)** | **2L Single-Agent Taxane****(n = 60)** | **2L Single-Agent,****Non-Taxane****(n = 38)** | **2LCombination,Taxane Based(n = 60)** | **2L Combination, Non-Taxane Based (n = 73)** |
| **Time to switch, months** |
|  Mean ± SD | 8.8 ± 8.0 | 7.2 ± 4.6 | 9.9 ± 8.7 | 7.7 ± 7.0 | 7.9 ± 7.9 |
|  Median (Q1, Q3) | 6.5 (3.2, 11.6) | 6.5 (4.0, 8.9) | 7.8 (3.7, 13.6) | 5.6 (2.56, 10.8) | 4.7 (2.5, 11.97) |
| **Treatment duration, months** |
|  Median (95% CI) | 1.8 (1.5, 2.1) | 1.5 (1.2, 2.1) | 1.4 (0.2, 2.3) | 1.6 (1.0, 2.1) | 2.6 (1.9, 3.5) |
| **Time between 1L and 2L, months** |
|  Mean ± SD | 5.2 ± 6.9 | 2.6 ± 3.6 | 6.9 ± 8.3 | 4.2 ± 5.8 | 5.4 ± 6.7 |
|  Median (Q1, Q3) | 2.1 (0.9, 6.9) | 1.4 (0.7, 2.6) | 6.0 (1.3, 9.9) | 1.4 (0.9, 5.3) | 1.8 (0.9, 7.7) |
| **Previous 1L treatment, n (%)** |
|  Cisplatin based | 87 (34) | 19 (32) | 14 (37) | 24 (40) | 21 (29) |

Abbreviations: 1L, first line; 2L, second line; Q1, first quartile; Q3, third quartile; SEER, Surveillance, Epidemiology, and End Results.



**Supplementary Fig. 1.** Kaplan-Meier plot of overall survival for most common 1L treatments in patients with metastatic bladder cancer with metastatic sites limited to lymph nodes (any T, N1-3, M0). Survival was measured from the index date. 1L cisplatin based and non-cisplatin–based treatments are plotted. 1L, first line.